

Bifiasthm™

Probiotic product • Allergic Asthma

A new treatment to improve the symptoms of allergic asthma



Lactobacillus salivarius LS01 (DSM 22775)
Bifidobacterium breve B632 (DSM 16604)

Allergic Asthma

Asthma is one of the most common chronic, non-communicable diseases, and affects around 334 million people worldwide. The global prevalence of self-reported, doctor-diagnosed asthma in adults is 4,3%, with wide variation between countries. (1)

Allergic asthma is the most common type of asthma. About 90% of kids with childhood asthma have allergies, compared with about 50% of adults with asthma. Allergic asthma is a complex disease characterized by a specific type of breathing problem that arises due to narrowing of the airways, their chronic inflammation, bronchial hyperactivity, and an infiltration of lymphocytes. The allergic reaction is due to the disruption of the TH1/Th2 balance towards a pronounced Th2 profile.

Functionality

BifiAsthm™ is a probiotic product with a specific immunomodulatory activity, targeted for allergic asthmatic subjects.

How to use

Two sachets a day, dissolved in a glass of water at room temperature or warm milk (max. 37° C), preferably one in the morning before breakfast and one at bedtime, for an intake period of at least 8 weeks; the supplementation can then be continued with one sachet a day in the morning before breakfast.

Review:

Papi A. et al. *Asthma. Lancet.* 2018 Feb 24;391(10122):783-800.



Powder in sachet/stick or capsule



Probiotics like nobody else



Probiotical S.p.A. Via E. Mattei, 3, 28100 Novara (NO), Italy - T: +39 0321 46 59 33
F: +39 0321 49 26 93 - email: support@probiotical.com - www.probiotical.com

Bifiasthm™

Probiotic product • Allergic Asthma

A new treatment to improve the symptoms of allergic asthma

Lactobacillus salivarius LS01 (DSM 22775)

Bifidobacterium breve B632 (DSM 16604)




Fig.1 Bidirectional Gut-Lung axis.

The metabolites like SCFAs produced by gut bacteria move through blood stream to stimulate immune response in lung and different factors from lung effect gut immune response. Apart from metabolites, the immune cells induced by multitude of antigens move through lymphatic duct between both these organs which leads to modulation of immune response in both organs.

Swadha Anand and Sharmila S. Mande.
Diet, Microbiota and Gut-Lung Connection.
Front. Microbiol., 19 September 2018

SCIENTIFIC REFERENCES

Human clinical trials

randomized placebo-controlled clinical trial on about 500 children with asthma: on-going

Clinical trials supporting the benefits of L. salivarius LS01 in other allergic disorders:

- 1) Drago L. et al. Effects of *Lactobacillus salivarius* LS01 (DSM 22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study. *Int J Immunopathol Pharmacol.* 2011 Oct-Dec;24(4):1037-48.
- 2) Drago L. et al. Changing of fecal flora and clinical effect of *L. salivarius* LS01 in adults with atopic dermatitis. *J Clin Gastroenterol.* 2012 Oct;46 Suppl:S56-63.
- 3) Niccoli AA et al Preliminary results on clinical effects of probiotic *Lactobacillus salivarius* LS01 in children affected by atopic dermatitis. *J Clin Gastroenterol.* 2014 Nov-Dec;48 Suppl 1:S34-6.
- 4) Fortuna MC et al. A case of Scalp *Rosacea* treated with low dose doxycycline and probiotic therapy and literature review on therapeutic options. *Dermatol Ther.* 2016 Jul;29(4):249-51
- 5) Iemoli E et al. Probiotics reduce gut microbial translocation and improve adult atopic dermatitis. *J Clin Gastroenterol.* 2012 Oct;46 Suppl:S33-40.

In vitro studies

- a) Drago L. et al., Strain-dependent release of cytokines modulated by *Lactobacillus salivarius* human isolates in an in vitro model, *BMC Res Notes.* 2010; 3:44.
- b) Drago L. et al., Immunomodulatory effects of *Lactobacillus salivarius* LS01 and *Bifidobacterium breve* BR03, alone and in combination, on peripheral blood mononuclear cells of allergic asthmatics, *Allergy Asthma Immunol Res.* 2015 July; 7(4):409-413.
- c) Drago et al. Effects of *Lactobacillus salivarius* LS01 (DSM 22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study. *Int J Immunopathol Pharmacol.* 2011 Oct-Dec;24(4):1037-48.

PLUS POINTS:

- Allergen Free product (patented technology)
- Natural product without side effects

SAFETY & QUALITY

- ✓ Strains with Qualified Presumption of Safety status (QPS list from European Food Safety Agency)
- ✓ No adverse effects in clinical studies
- ✓ Produced according to the highest quality standards:
- ✓ GMP
- ✓ ISO 14001
- ✓ ISO 9001
- ✓ ISO 22000

